For the quarter ending 2026-03-31, LPCN made $119,397 in revenue. -$3,683,533 in net income. Net profit margin of -3085.11%.
| Income Statement | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 |
|---|---|---|---|---|
| Total revenues | 119,397 | 870,542.5* | 114,574 | 622,849 |
| Research and development | 2,764,394 | 1,320,619.75* | 2,707,777 | 2,136,769 |
| General and administrative | 1,204,467 | 1,276,732* | 767,837 | 890,433 |
| Total operating expenses | 3,968,861 | 2,597,351.75* | 3,475,614 | 3,027,202 |
| Operating loss | -3,849,464 | -1,726,809.25* | -3,361,040 | -2,404,353 |
| Unrealized loss on warrant liability | - | - | - | 0 |
| Interest and investment income | 177,570 | 184,806.5 | 174,208 | 198,637 |
| Total other income | 177,570 | 184,806.5* | 174,208 | 198,637 |
| Loss before income tax expense | -3,671,894 | -1,542,002.75* | -3,186,832 | -2,205,716 |
| Income tax expense | - | 200* | - | 0 |
| Net loss attributable to common shareholders | -3,671,894 | -1,542,202.75* | - | - |
| Net unrealized loss on marketable investment securities | -11,639 | -1,173.25* | - | - |
| Net loss attributable to common shareholders | - | - | -3,186,832 | -2,205,716 |
| Comprehensive loss | -3,683,533 | -1,543,376 | - | - |
| Basic EPS | -0.54 | -0.277 | -0.59 | -0.41 |
| Diluted EPS | -0.54 | -0.243 | -0.59 | -0.41 |
| Basic Average Shares | 6,795,002 | 5,581,507 | 5,413,149 | 5,351,957 |
| Diluted Average Shares | 6,795,002 | 6,359,608 | 5,413,149 | 5,351,957 |
Lipocine Inc. (LPCN)
Lipocine Inc. (LPCN)